Interlude Biopharma Unveils New Phase 3 Trial at Celiac Symposium

Interlude Biopharma's Exciting Launch at the International Celiac Disease Symposium



On November 19, 2026, Mark Paresky, co-founder and executive chairman of Interlude Biopharma, heralded the company's public debut at the 21st International Celiac Disease Symposium (ICDS 2026) held in Melbourne, Australia. Amidst the gathering of leading scientists, clinicians, and patient organizations, Interlude Biopharma presented its groundbreaking plans for a Phase 3 clinical trial focused on the prevention of damage associated with gluten exposure in individuals with celiac disease.

Understanding Celiac Disease and Current Treatments


Celiac disease is an autoimmune disorder affecting approximately 1% of the global population, characterized by the body's abnormal response to gluten, a protein found in wheat, rye, and barley. The only current treatment is a strict gluten-free diet, which remains challenging for many due to accidental gluten exposure leading to persistent symptoms and gut injury. Recognizing the limitations of existing treatment strategies, particularly the rigid dietary restrictions that do not prevent damage from gluten, Interlude aims to offer new hope.

Introducing Larazotide Acetate


At the heart of Interlude's research is larazotide acetate, an innovative oral peptide that regulates the tight junctions of the intestinal lining, known for its ability to prevent gluten-induced injury. This drug candidate works by inhibiting zonulin, a protein that plays a critical role in regulating intestinal barrier function. By addressing the issue at an upstream level, larazotide acetate has the potential to prevent the immune response triggered by gluten exposure, which could have implications extending beyond celiac disease to other chronic inflammatory conditions.

The Phase 3 Clinical Trial


Scheduled to begin in early 2027, the Phase 3 trial is designed to rigorously evaluate the efficacy of larazotide acetate in preventing gluten-induced intestinal damage. The trial will involve 414 adolescents and adults aged 12 to 80 with well-controlled celiac disease, taking place across up to 100 sites in the United States. Participants will consume a placebo or various doses of larazotide acetate while being exposed to gluten, and researchers will carefully monitor their symptom management and gut health via a comprehensive Celiac Disease Symptom Diary.

Dr. Alessio Fasano, a revered pediatric gastroenterologist and advocate for celiac disease research, supports this innovative trial design, emphasizing the need for preventive approaches rather than reactive treatments that commence after symptoms occur. This preventive methodology is a first in the field of celiac research and aligns with FDA recommendations, signifying a paradigm shift in the way the disease may be approached in clinical settings.

Collaboration and Future Directions


As the trial date approaches, Interlude Biopharma is actively engaging with clinical sites and celiac disease patient organizations to ensure comprehensive support and collaboration. Paresky shared his personal connection to celiac disease, noting how his daughter's diagnosis sparked the creation of their company and their commitment to improving lives affected by this challenging condition.

A Global Platform for Celiac Disease


The ICDS 2026 serves as an invaluable global platform for discussing the latest advancements in celiac disease research. With its innovative approach, Interlude Biopharma not only aims to forge new paths in treating celiac disease but also represents a beacon of hope for the many families grappling with the lifelong implications of gluten exposure. The outcomes of the Phase 3 trial could potentially reshape the clinical landscape, offering new strategies to effectively manage and prevent gluten-related complications.

For further updates on this significant endeavor and to learn more about the implications of larazotide acetate and celiac disease research, visit Interlude Biopharma’s official website or ICDS 2026’s resources.

In conclusion, the strides Interlude Biopharma is making at this pivotal symposium signal an essential step toward a future where prevention, rather than just management, of celiac disease becomes a reality. Stay tuned as we follow Interlude Biopharma’s journey through this groundbreaking trial!

Topics Health)

【About Using Articles】

You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.

【About Links】

Links are free to use.